Relation Between Serum Uric Acid and Metabolic Syndrome in Type 2 DM

September 29, 2020 updated by: Esraa Tarek Mahmoud Ahmed, Assiut University

the Association Between Serum Uric Acid Levels and the Risk of Metabolic Syndrome in Type 2 Diabetes Mellitus

This study will be undertaken to evaluate the association of serum uric acid (SUA) level with metabolic risk factors in patients with type 2 diabetes and their relation to eGFR status

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

Metabolic syndrome (syndrome X, insulin resistance) is a multifactorial disease with multiple risk factors that arises from insulin resistance accompanying abnormal adipose deposition and function . It comprises a combination of risk factors for coronary heart disease, as well as for diabetes type 2 , fatty liver, and several cancers.

Sign and symptoms are ; Hypertension... Hyperglycemia.. Hypertriglyceridemia... Reduced high-density lipoprotein cholesterol (HDL-C).. Abdominal obesity... Chest pain or shortness of breath: Suggesting the rise of cardiovascular and other complications.. The prevalence of the metabolic syndrome is often more in the urban population of some developing countries than in its Western counterparts . The syndrome feeds into the spread of the diseases like type 2 diabetes, coronary diseases, stroke, and other disabilities. The present trend is not sustainable unless a magic cure is found (unlikely) or concerted global/governmental/societal efforts are made to change the lifestyle that is promoting it.

There has been a renewed interest in the association of uric acid with diabetes and its complications. Uric acid is a product of purine metabolism. Increased serum uric acid (SUA) level has been shown to be associated with hypertension(1) cardiovascular disease (CVD)(2) and chronic kidney disease(3) . Elevated SUA level was also associated with metabolic syndrome in both normal subjects as well as in patients with type 2 diabetes. And with type 2 diabetes mellitus(4) Higher SUA level independently predicted the incidence of type 2 diabetes in subjects who had abnormal fasting glucose levels (5) . It has been shown that SUA levels are higher in patients with prediabetic conditions and in patients with type 2 diabetes compared with the level in normal controls (6) . SUA level has been shown to be positively associated with all cause mortality risk, but cardiovascular mortality was associated with SUA level only among those with hyperglycemia (prediabetes and type 2 diabetes)(8) . Hyperuricemia has been found to be associated with risk factors of diabetes such as obesity and insulin resistance(9) . Uric acid has also been reported to be involved in the endothelial dysfunction by impairing nitric oxide production and causing inflammation(10) , These effects of uric acid likely account for its impact on CVD incidence(11) . In acute ischaemic stroke, the survivors with both lower (<4.7 mg/dL) and higher (>6.7 mg/dL) baseline SUA levels had poor outcomes after a 12 month follow up when compared with those who had SUA levels in the range of 4.7-6.7 mg/dL. This is suggestive of the protective nature of uric acid when it is within the optimal range.

SUA level was positively associated with increased incidence of cardiovascular diseases (CVD) in patients with abnormal eGFR (<90 mL/min/1.73 m2) . HbA1c was found to be inversely associated with hyperuricemia in patients with normal eGFR level (≥90 mL/min/1.73 m2). Incidence of metabolic syndrome did not show any relationship with SUA level. However, the incidence of hypertension, a component of metabolic syndrome, was significantly higher among patients with hyperuricemia. Waist circumference and serum triglycerides were higher, whereas serum high-density lipoprotein level was lower in patients with higher SUA level. (12) Serum urea and creatinine were elevated in hyperuricemic patients, suggesting impaired kidney function. Hyperuricemia is known to be associated with the decrease in kidney function (13) and because chronic kidney disease itself elevates SUA level,(14) it is difficult to interpret the causes of the elevated serum urea and creatinine in hyperuricemia. However, eGFR values were only slightly lower in hyperuricemic patients. Correlation analysis showed that both serum urea and creatinine levels were positively associated with SUA level.. This association was found to be significant in patients with normal eGFR levels as well. However, eGFR appears to be negatively associated with SUA level in patients with abnormal eGFR level. Decreased urine output leads to decreased excretion of uric acid, resulting in the elevated SUA level. Therefore, reduction in eGFR may increase SUA levels in these patients.

The importance of uric acid has been increasingly appreciated because of its association with the development of diabetes mellitus and related diseases. SUA level and susceptibility to hyperuricemic conditions depend on the factors such as gender, age and ethnicity. (15) With the increasing incidence of diabetes studying the impact of hyperuricemia in patients with diabetes is necessary.

Study Type

Observational

Enrollment (Anticipated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: salah abdelazeem, professor
  • Phone Number: 01064559917
  • Email: argoons@yahoo.com

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

30 years to 90 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

patient will be collected randomly from outpatient clinics of diabetic center of assiut univeristy

Description

Inclusion Criteria:

  • type 2 diabetic patient

Exclusion Criteria:

  1. patients with type 1 diabetes
  2. gestational diabetes
  3. patients with drug affecting uric acid levels
  4. secondary diabetes

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
the association of serum uric acid (SUA) level with metabolic risk factors in patients with type 2 diabetes
Time Frame: baseline
the incidence of hypertension, a component of metabolic syndrome, is significantly higher among patients with hyperuricemia. Waist circumference and serum triglycerides are higher, whereas serum high-density lipoprotein level is lower in patients with higher SUA level.
baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ANTICIPATED)

October 1, 2020

Primary Completion (ANTICIPATED)

October 1, 2021

Study Completion (ANTICIPATED)

November 1, 2021

Study Registration Dates

First Submitted

September 29, 2020

First Submitted That Met QC Criteria

September 29, 2020

First Posted (ACTUAL)

October 5, 2020

Study Record Updates

Last Update Posted (ACTUAL)

October 5, 2020

Last Update Submitted That Met QC Criteria

September 29, 2020

Last Verified

September 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • metabolic risk factor

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Metabolic Syndrome

Clinical Trials on Serum uric acid levels ,HBA1C , fasting plasma glucose ,lipid profile , creatinine level

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cote d'Ivoire

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe